NCT05631327View on ClinicalTrials.gov

A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

April 24, 2024

Study Completion Date

April 24, 2024

Conditions
Advanced Solid TumorMetastatic Solid Tumor
Interventions
DRUG

JZP341

JZP341 will be administered as a single, intravenous infusion over 2 hours.

Trial Locations (8)

19107

Thomas Jefferson University/Sidney Kimmel Cancer Center, Philadelphia

21201

University of Maryland Medical Center, Baltimore

34232

Florida Cancer Specialists - Sarasota, Sarasota

37203

Tennessee Oncology - Nashville, Nashville

73106

Oklahoma University- Oklahoma City, Oklahoma City

80218

SCRI HealthOne, Denver

02215

Dana Farber Cancer Institute, Boston

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY